MERCURY LAB. | DIVIS LABORATORIES | MERCURY LAB./ DIVIS LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 21.9 | 86.4 | 25.3% | View Chart |
P/BV | x | 2.2 | 11.7 | 18.4% | View Chart |
Dividend Yield | % | 0.4 | 0.5 | 76.5% |
MERCURY LAB. DIVIS LABORATORIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
MERCURY LAB. Mar-24 |
DIVIS LABORATORIES Mar-24 |
MERCURY LAB./ DIVIS LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,303 | 4,072 | 32.0% | |
Low | Rs | 535 | 2,825 | 18.9% | |
Sales per share (Unadj.) | Rs | 629.7 | 295.5 | 213.1% | |
Earnings per share (Unadj.) | Rs | 47.1 | 60.3 | 78.2% | |
Cash flow per share (Unadj.) | Rs | 70.6 | 74.5 | 94.7% | |
Dividends per share (Unadj.) | Rs | 3.50 | 30.00 | 11.7% | |
Avg Dividend yield | % | 0.4 | 0.9 | 43.8% | |
Book value per share (Unadj.) | Rs | 423.7 | 511.2 | 82.9% | |
Shares outstanding (eoy) | m | 1.20 | 265.47 | 0.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.5 | 11.7 | 12.5% | |
Avg P/E ratio | x | 19.5 | 57.2 | 34.1% | |
P/CF ratio (eoy) | x | 13.0 | 46.3 | 28.1% | |
Price / Book Value ratio | x | 2.2 | 6.7 | 32.2% | |
Dividend payout | % | 7.4 | 49.8 | 14.9% | |
Avg Mkt Cap | Rs m | 1,103 | 915,508 | 0.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 142 | 10,940 | 1.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 756 | 78,450 | 1.0% | |
Other income | Rs m | 11 | 3,390 | 0.3% | |
Total revenues | Rs m | 766 | 81,840 | 0.9% | |
Gross profit | Rs m | 90 | 22,060 | 0.4% | |
Depreciation | Rs m | 28 | 3,780 | 0.7% | |
Interest | Rs m | 4 | 40 | 9.6% | |
Profit before tax | Rs m | 69 | 21,630 | 0.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 13 | 5,630 | 0.2% | |
Profit after tax | Rs m | 57 | 16,000 | 0.4% | |
Gross profit margin | % | 12.0 | 28.1 | 42.5% | |
Effective tax rate | % | 18.3 | 26.0 | 70.3% | |
Net profit margin | % | 7.5 | 20.4 | 36.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 398 | 101,520 | 0.4% | |
Current liabilities | Rs m | 129 | 17,550 | 0.7% | |
Net working cap to sales | % | 35.6 | 107.0 | 33.3% | |
Current ratio | x | 3.1 | 5.8 | 53.2% | |
Inventory Days | Days | 1 | 12 | 10.5% | |
Debtors Days | Days | 1,056 | 10 | 10,522.8% | |
Net fixed assets | Rs m | 281 | 57,850 | 0.5% | |
Share capital | Rs m | 12 | 530 | 2.3% | |
"Free" reserves | Rs m | 496 | 135,180 | 0.4% | |
Net worth | Rs m | 508 | 135,710 | 0.4% | |
Long term debt | Rs m | 29 | 0 | - | |
Total assets | Rs m | 680 | 159,370 | 0.4% | |
Interest coverage | x | 19.1 | 541.8 | 3.5% | |
Debt to equity ratio | x | 0.1 | 0 | - | |
Sales to assets ratio | x | 1.1 | 0.5 | 225.9% | |
Return on assets | % | 8.9 | 10.1 | 88.3% | |
Return on equity | % | 11.1 | 11.8 | 94.3% | |
Return on capital | % | 13.6 | 16.0 | 85.2% | |
Exports to sales | % | 24.8 | 85.2 | 29.1% | |
Imports to sales | % | 0 | 24.0 | 0.0% | |
Exports (fob) | Rs m | 187 | 66,870 | 0.3% | |
Imports (cif) | Rs m | NA | 18,810 | 0.0% | |
Fx inflow | Rs m | 187 | 66,870 | 0.3% | |
Fx outflow | Rs m | 3 | 19,160 | 0.0% | |
Net fx | Rs m | 184 | 47,710 | 0.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 82 | 12,610 | 0.7% | |
From Investments | Rs m | -63 | -2,690 | 2.3% | |
From Financial Activity | Rs m | -10 | -7,990 | 0.1% | |
Net Cashflow | Rs m | 9 | 1,930 | 0.5% |
Indian Promoters | % | 73.7 | 51.9 | 142.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 38.3 | - | |
FIIs | % | 0.0 | 17.3 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 26.3 | 48.1 | 54.7% | |
Shareholders | 1,345 | 278,899 | 0.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare MERCURY LAB. With: CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | MERCURY LAB. | Divis Laboratories | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -1.65% | 1.35% | 0.11% |
1-Month | -6.99% | 0.88% | -3.22% |
1-Year | 16.85% | 60.59% | 42.65% |
3-Year CAGR | 14.88% | 8.49% | 19.86% |
5-Year CAGR | 28.51% | 27.91% | 25.90% |
* Compound Annual Growth Rate
Here are more details on the MERCURY LAB. share price and the Divis Laboratories share price.
Moving on to shareholding structures...
The promoters of MERCURY LAB. hold a 73.7% stake in the company. In case of Divis Laboratories the stake stands at 51.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of MERCURY LAB. and the shareholding pattern of Divis Laboratories.
Finally, a word on dividends...
In the most recent financial year, MERCURY LAB. paid a dividend of Rs 3.5 per share. This amounted to a Dividend Payout ratio of 7.4%.
Divis Laboratories paid Rs 30.0, and its dividend payout ratio stood at 49.8%.
You may visit here to review the dividend history of MERCURY LAB., and the dividend history of Divis Laboratories.
For a sector overview, read our pharmaceuticals sector report.
On Thursday, Indian share markets traded lower throughout the trading session and ended on a weak note.